

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THE STUDY	1
SCOPE OF REPORT	1
SCOPE OF REPORT (CONTINUED)	2
INTENDED AUDIENCE.....	3
METHODOLOGY AND INFORMATION SOURCES.....	3
ANALYST CREDENTIALS.....	4
RELATED REPORTS	4
BCC ONLINE SERVICES.....	4
DISCLAIMER	5
 CHAPTER TWO: EXECUTIVE SUMMARY.....	 6
<i>SUMMARY TABLE GLOBAL BIOLOGICS MARKET FORECAST BY TYPE OF PRODUCT, THROUGH 2015 (\$ BILLIONS)</i>	 6
<i>SUMMARY FIGURE GLOBAL BIOLOGICS MARKET FORECAST BY TYPE OF PRODUCT, 2009-2015 (\$ BILLIONS)</i>	 7
EXECUTIVE SUMMARY (CONTINUED)	8
 CHAPTER THREE: OVERVIEW	 9
BIOLOGICS: LEADERSHIP IN DRUG DEVELOPMENT	9
BIOLOGICS: LEADERSHIP IN DRUG ... (CONTINUED)	10
<i>TABLE 1 BIOPHARMACEUTICAL MARKET, ESTIMATED VALUE AND FORECAST, THROUGH 2015 (\$ BILLIONS)</i>	 11
BIOLOGICS: TYPES OF PRODUCTS	11
MONOCLONAL ANTIBODIES (MABS)	11
<i>FIGURE 1 DIAGRAM OF TYPICAL ANTIBODY STRUCTURE</i>	 12
THERAPEUTIC PROTEINS.....	13
Hemopoietic Growth Factors.....	14
Cytokines	14
Blood Factors	15
VACCINES	16
Traditional Vaccines.....	16
Novel Vaccine Technologies	16
Main Product Classes.....	17
<i>TABLE 2 BIOPHARMACEUTICAL MARKET, ESTIMATED VALUE AND FORECAST THROUGH 2010 (\$ BILLIONS)</i>	 17
CHALLENGES WITH RNAI.....	17
ORPHAN DRUG DESIGNATION	18
 CHAPTER FOUR: INDUSTRY STRUCTURE AND COMPETITIVE ANALYSIS.....	 19
INDUSTRY STRUCTURE	19
THE ORIGINS OF BIOTECHNOLOGY.....	20

INVOLVEMENT OF BIG PHARMA	21
<i>TABLE 3 COMPANY DEPENDENCE ON BIOPHARMACEUTICALS (% OF TOTAL REVENUE ARISING FROM BIOPHARMACEUTICALS)</i>	21
BIOPHARMA SPECIALIST COMPANIES	22
<i>TABLE 4 CURRENT LEADERS</i>	22
M&A ACTIVITY IN THE BIOLOGICAL FIELD	23
M&A ACTIVITY IN THE BIOLOGICAL FIELD (CONTINUED).....	24
EXPECTED M&A TRENDS	25
Abbot Flu Vaccine Business on the Market	26
Abbot Flu Vaccine ... (Continued).....	27
OPPORTUNITY AND THREAT FROM BIOSIMILARS	28
RATIONALE FOR BIOSIMILAR DEVELOPMENT.....	29
<i>TABLE 5 BIOLOGICS FACING THE LAUNCH OF BIOSIMILARS, 2001- 2006</i>	29
<i>TABLE 5 (CONTINUED)</i>	30
BIOIMILARS: REGULATORY UPDATE	30
U.S. FDA.....	30
U.S. FDA (Continued).....	31
European Biosimilar Regulatory Guidance.....	32
SELECTED BIOSIMILAR DEVELOPMENTS AND INTRODUCTIONS	33
EPO	33
G-CSF.....	33
Interferons	33
HGH	33
MONOCLONAL ANTIBODIES	34
CHAPTER FIVE: MARKETS BY PRODUCT TYPE AND DISEASE	35
MARKET TRENDS: GROWTH DRIVERS, AND RESISTORS.....	35
<i>TABLE 6 BIOPHARMACEUTICAL MARKET, ESTIMATED VALUE AND FORECAST, THROUGH 2015 (\$ BILLIONS)</i>	36
MARKET STATUS BY PRODUCT GROUP	36
MONOCLONAL ANTIBODIES	36
<i>TABLE 7 LEADING MONOCLONAL ANTIBODY PRODUCTS IN 2009 (\$ MILLIONS)</i>	37
Anticancer	37
Stand-alone Antibodies.....	38
• Rituxan.....	38
• Campath.....	39
Stand-alone Antibodies for Specific Antigen Binding.....	39
• Herceptin.....	40
• Erbitux	40
• Avastin	41

Avastin (Continued)	42
Radio-labeled Antibodies	43
• Zevalin	43
• Bexxar	44
• ProstaScint.....	44
Chemolabeled Antibodies	44
Immunotoxins	44
• Mylotarg.....	45
Conjugated Antibodies.....	45
Anti-TNF.....	45
<i>TABLE 8 MARKETED ANTI-TNF MABS.....</i>	<i>46</i>
Market Review of Monoclonal Antibodies	46
<i>TABLE 9 GLOBAL MARKET FORECAST FOR MABS, THYROUGH</i>	
<i>2015 (\$ BILLIONS).....</i>	<i>47</i>
<i>TABLE 10 MAB MARKET LEADERS, 2009 (\$ BILLIONS).....</i>	<i>47</i>
THERAPEUTIC PROTEINS	47
<i>TABLE 11 HEMOPOIETIC GROWTH FACTORS (\$ MILLIONS).....</i>	<i>48</i>
Cytokines	48
<i>TABLE 12 CYTOKINES SALES 2009 (\$ MILLIONS)</i>	<i>49</i>
Enbrel.....	49
Betaseron	49
Pegasys.....	50
Antihemophilia Products.....	50
<i>TABLE 13 ANTIHEMOPHILIA PRODUCTS SALES, 2009.....</i>	<i>50</i>
NovoSeven	51
Kogenate.....	51
Recombinate.....	51
Advate.....	51
Growth Hormones.....	52
<i>TABLE 14 GROWTH FACTOR PRODUCT SALES, 2009</i>	<i>52</i>
Genotropin.....	52
Insulin	52
Erythropoietin.....	53
Growth Hormone	54
<i>TABLE 15 HUMAN GROWTH HORMONE PRODUCTS.....</i>	<i>54</i>
Cytokines	55
<i>TABLE 16 APPROVED CYTOKINES.....</i>	<i>55</i>
Blood Factors	56
<i>TABLE 17 BLOOD FACTORS FOR HEMOPHILIA TREATMENT.....</i>	<i>56</i>
Market Review of Therapeutic Proteins.....	56
<i>TABLE 18 GLOBAL THERAPEUTIC PROTEINS MARKET AND</i>	
<i>FORECAST, THROUGH 2015 (\$ BILLIONS).....</i>	<i>57</i>
<i>TABLE 19 THERAPEUTIC PROTEINS MARKET, 2009 MARKET,</i>	
<i>SALES BY CLASS (\$ BILLIONS/%).....</i>	<i>57</i>

VACCINES	57
Pevnar.....	58
Gardasil.....	58
Vaxigrip.....	58
Engerix.....	58
Production Issues.....	59
Opportunities in Emerging Markets	59
Adjuvant Developments	60
Therapeutic Vaccines	60
Influenza	61
<i>TABLE 20 LEADING VACCINE PRODUCT SALES, 2009 (\$</i> <i>MILLIONS/%).....</i>	<i>61</i>
<i>TABLE 21 LEADING VACCINE PRODUCTS, SALES 2009 (\$</i> <i>MILLIONS).....</i>	<i>62</i>
<i>TABLE 22 GLOBAL VACCINES MARKET AND FORECAST,</i> <i>THROUGH 2015 (\$ BILLIONS)</i>	<i>63</i>
GEOGRAPHIC MARKET ANALYSIS.....	63
<i>TABLE 23 GEOGRAPHIC DISTRIBUTION: TOTAL BIOLOGICS</i> <i>MARKET (%).....</i>	<i>64</i>
<i>TABLE 24 GEOGRAPHIC MARKET FORECAST: TOTAL BIOLOGICS</i> <i>MARKET (\$ BILLIONS).....</i>	<i>64</i>
CHAPTER SIX: BIOLOGICS MANUFACTURING	65
INTRODUCTION	65
BIOPHARMACEUTICAL MANUFACTURING PROCESS	66
THE PREPARATION PROCESS	66
Cell Banking and Seed Culture	66
Production.....	67
Cell Culture Formats.....	67
Batch and Continuous Processing.....	68
Perfusion and Fed-batch Mode.....	68
<i>TABLE 25 RECOMBINANT THERAPEUTIC PRODUCTS USING</i> <i>PERFUSION METHOD</i>	<i>69</i>
• Perfusion Methods.....	69
• Fed-batch Methods.....	69
<i>TABLE 26 RECOMBINANT THERAPEUTIC PRODUCTS USING FED-</i> <i>BATCH METHOD</i>	<i>70</i>
Harvest and Concentration.....	70
THE FINISHING PROCESS	71
PURIFICATION OF BIOPHARMACEUTICALS.....	72
AUTOMATED PROCESSING SYSTEMS—SKIDS	73
FORMULATION	74
LYOPHILIZATION	75
CRYOGRANULATION.....	75
SPRAY-DRYING	75

UNDERCOOLING	75
PROCESS INTEGRATION: THE CRITICAL ACTIVITY.....	75
EXPRESSION SYSTEMS FOR THERAPEUTIC PROTEIN PRODUCTION.....	76
<i>FIGURE 2 DECISION FRAMEWORK FOR EXPRESSION SYSTEM SELECTION</i>	77
Microbial Therapeutic Protein Production	78
<i>E.coli</i> Advantages for Microbial Production	78
• Fast Accumulation	78
• Safety Advantage	78
• Growth on Inexpensive Carbon Sources.	79
• Propensity for High-cell-density Fermentations.	79
• Simple Process Scale-up	79
<i>TABLE 27 MARKETED BIOPHARMACEUTICALS USING E.COLI EXPRESSION SYSTEM</i>	79
MAMMALIAN CELL THERAPEUTIC PROTEIN PRODUCTION.....	80
<i>TABLE 28 MARKETED BIOPHARMACEUTICALS USING CHO CELL LINE EXPRESSION SYSTEM, 1998-2004</i>	80
EMERGING PRODUCTION SYSTEMS.....	81
<i>Pichia</i> and Filamentous Fungi.....	81
<i>TABLE 29 MARKETED BIOPHARMACEUTICALS USING YEAST EXPRESSION SYSTEM</i>	82
Transgenic Protein Production Systems	82
Transgenic Plants	83
<i>TABLE 30 PLANT-BASED TRANSGENIC COMPANIES AND THEIR PIPELINE OF RECOMBINANT PROTEINS</i>	84
Transgenic Animals	84
<i>TABLE 31 THERAPEUTIC PROTEINS PRODUCED IN TRANSGENIC ANIMALS</i>	85
<i>TABLE 32 MARKETED BIOPHARMACEUTICALS USING MURINE HYBRIDOMA EXPRESSION SYSTEM</i>	86
<i>TABLE 33 MARKETED BIOPHARMACEUTICALS USING MURINE MYELOMA EXPRESSION SYSTEM</i>	87
CHAPTER SEVEN: PIPELINE ANALYSIS	88
SUMMARY.....	88
OVERVIEW.....	88
MONOCLONAL ANTIBODIES	89
TECHNOLOGY.....	89
HUMAN ANTIBODIES	89
ANTIBODY FRAGMENTS	90
CONJUGATED ANTIBODIES.....	90

ANTIBODIES IN ADVANCED DEVELOPMENT.....	91
<i>TABLE 34 MABS NEAR TO MARKET LAUNCH, 2010</i>	<i>92</i>
PIPELINE ACTIVITY.....	92
Oncology.....	92
<i>TABLE 35 ANTICANCER MONOCLONAL ANTIBODY PRODUCTS IN</i> <i>PHASE III TRIALS</i>	<i>92</i>
Abagovomab	93
Anyara	93
Humax EGFr.....	93
Rencarex.....	94
Ipilimumab.....	94
Ipilimumab (Continued).....	95
Ipilimumab (Continued).....	96
Multiple Therapies for Prostate Cancer	97
Provenge	97
Prolia	98
Others.....	98
Others (Continued)	99
INFLAMMATION AND IMMUNOLOGY.....	100
<i>TABLE 36 IMMUNE SYSTEM RELATED MONOCLONAL ANTIBODY</i> <i>PRODUCTS IN PHASE III TRIALS</i>	<i>100</i>
Benlysta	100
Epratuzumab	100
Ocrelizumab.....	101
Reslizumab.....	102
Others.....	102
OTHER INDICATIONS.....	103
<i>TABLE 37 MAB PRODUCTS IN CLINICAL DEVELOPMENT FOR</i> <i>NOVEL INDICATIONS</i>	<i>103</i>
Bapineuzumab	103
Otelixizumab.....	104
Pagibaximab	104
Tanezumab.....	105
HEPATITIS C.....	105
HCV: Current Standard of Care	105
Telaprevir and Boceprevir.....	106
New Drug Class: NS5A inhibitors	107
Danoprevir	107
Efficacy of Novel Agents in Hepatitis C.....	108
Others.....	108
MULTIPLE SCLEROSIS.....	109
First Data Presented from AAN for Oral MS Therapy.....	109
Gilenia	109
Oral Cladribine	110

Favorable Data for Acorda's Ampyra	111
THERAPEUTIC PROTEINS.....	112
TECHNOLOGY.....	112
<i>TABLE 38 CYTOKINES IN DEVELOPMENT</i>	112
MULTIKINE	113
CINTREDEKIN BESUDOTOX.....	113
RILONACEPT (IL-1 TRAP).....	114
PREVASCAR.....	115
PRX302	115
HEMOPOIETIC GROWTH FACTORS.....	116
<i>TABLE 39 THERAPEUTIC PROTEINS IN DEVELOPMENT</i>	116
<i>TABLE 39 (CONTINUED)</i>	117
Replagal	118
Joulferon	118
CYT107.....	119
Talactoferrin	120
Taspoglutide.....	120
VACCINES.....	121
<i>TABLE 40 VACCINES IN LATE-STAGE DEVELOPMENT</i>	121
<i>TABLE 40 (CONTINUED)</i>	122
HETEROLOGOUS PRIME-BOOST SCHEMES	122
NEW ADJUVANTS.....	122
NEW VACCINES AGAINST EXISTING TARGETS	123
Influenza	123
H1N1 Swine Flu.....	124
Human Papillomavirus (HPV).....	124
Pneumococcus	124
Meningococcus	125
VACCINES AGAINST NEW TARGETS.....	125
HIV Vaccines	125
HIV Vaccines (Continued)	126
HIV Vaccines (Continued)	127
HIV Vaccines (Continued)	128
<i>TABLE 41 NEW VACCINE TECHNOLOGIES</i>	129
Cancer Vaccines.....	129
Malaria.....	130
Tuberculosis	130
VACCINES IN LATE-STAGE DEVELOPMENT.....	131
Menveo	131
Cervarix	132
<i>TABLE 42 VACCINES IN LATE STAGE DEVELOPMENT</i>	132
<i>TABLE 42 (CONTINUED)</i>	133
Ixiaro/Jespect.....	133
Stimuvax	133

Stimuvax (Continued).....	134
---------------------------	-----

CHAPTER EIGHT: COMPANY PROFILES	135
ABBOTT LABORATORIES.....	135
ADVAXIS, INC.....	136
AGENNIX AG	136
AKEBIA THERAPEUTICS, INC.	137
AMGEN INC	137
APOGENIX GMBH.....	138
BAXTER INTERNATIONAL, INC.	138
ERYTECH PHARMA.....	139
BAYER SCHERING PHARMA AG.....	139
BIOGEN IDEC, INC.....	140
BIOINVENT INTERNATIONAL AB.....	140
BIOVITRUM AB	141
CELLDEX THERAPEUTICS, INC.	142
CSL BEHRING	143
CYTHERIS SA	143
DEBIOPHARM GROUP	144
ELI LILLY & CO.....	144
GENMAB A/S.....	145
DYAX CORP.....	145
GENZYME CORPORATION	146
GLAXOSMITHKLINE PLC	147
HAWAII BIOTECH, INC.....	148
HELIX BIOPHARMA CORP.....	148
HUMAN GENOME SCIENCES, INC.....	149
IMMUTEP S.A.	149
INTERCELL AG	150
IMMUNOVACCINE TECHNOLOGIES, INC.	151
H. LUNDBECK A/S	151
GLYCOTOPE GMBH.....	152
IMCLONE SYSTEMS, INC.....	152
IPSEN.....	153
IMMUNOGEN INC	153
INNATE PHARMA	154
F. HOFFMANN-LA ROCHE, LTD.....	154
MEDAREX, INC.	155
MERCK & CO, INC.	156
MERCK SERONO S.A.....	156
NOVARTIS AG	157
NOVO NORDISK A/S.....	158
PFIZER, INC.....	158
SEATTLE GENETICS, INC.....	159
TOLERX, INC.	160

TRUBION PHARMACEUTICALS, INC.....	161
OCTAPHARMA AG	161
PHOSPHAGENICS, LIMITED	162
PROTEON THERAPEUTICS, INC.	162
SANOFI-AVENTIS	163
SOLIGENIX, INC.	164
STALLERGENES	164
SHIRE PLC	165
TEVA PHARMACEUTICAL INDUSTRIES, LTD.	165
THROMBOGENICS NV	166
TRIPEP AB	167
VICAL, INC.....	167
UCB S.A.	168
WILEX AG.....	169
XCELLEREX, INC.....	170
ZYMOGENETICS, INC.	170
ZYMOGENETICS, INC. (CONTINUED).....	171